精品国产一区二区桃色

Journal News

Stabilizing the enzyme in fish odor syndrome

Mussa Quareshy
By Mussa Quareshy
Dec. 6, 2020

Fish odor syndrome, or trimethylaminuria, is a disease in which the liver cannot break down the smelly chemical trimethylamine, or TMA, that is produced by enzymes from bacteria residing in the gut. There is no cure for fish odor syndrome, which gives people an unpleasant fishy smell that can affect breath, sweat, urine and vaginal fluids.

FishOdor-226x600.jpg
University of Warwick
Top: protein crystals of CntA enzyme; middle: a cartoon depiction of CntA enzyme in its functional trimeric state; bottom: detailed view of carnitine bound in the active site of CntA prior to cleavage.

Our research team at the University of Warwick is working to prevent the syndrome through studying the enzyme in the gut that produces trimethylamine.

Fish odor syndrome starts when an enzyme pathway in the gut called CntA/B produces TMA. The enzyme breaks down a TMA precursor called L-carnitine, which is found in dairy, fish and meat. If an individual lacks a functional liver enzyme called FMO3, they cannot degrade TMA into a non-smelly chemical form, trimethylamine oxide, or TMAO. The TMA then builds up in the body and ends up in bodily fluids.

In, published in the Journal of Biological Chemistry, our team in at Warwick's School of Life Sciences focused on the CntA protein of the CntA/B enzyme, to stabilize and study it.

CntA/B is a notoriously hard enzyme to study, but once it was stabilized, we were able to gain insight into how CntA perceives its L-carnitine substrate with a 3D crystal structure model, and by studying the complete electron transfer pathway, we could see how the protein is able to turn over TMA.

Now that we understand how exactly TMA is produced in the gut and that the enzyme can be inhibited, there are grounds for further research into future discovery of drugs targeting the TMA-producing enzyme in the human gut.

We have identified novel, drug-like inhibitors that can inhibit CntA function and thus TMA formation with the potential to attenuate TMA formation in the gut microbiome. This is vital not only for people who have fish odor syndrome, but also because TMA can accelerate atherosclerosis and heart disease.
 

This article was adapted from a University of Warwick press release. Read the original .

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Mussa Quareshy
Mussa Quareshy

Mussa Quareshy grew up in Malawi, then moved to the U. K. where he earned a master’s degree in pharmaceutical sciences at the University of Leicester and a Ph.D. at Warwick University, studying the plant hormone Auxin and its receptor. He is a postdoc research fellow in Yin Chen’s lab in the School of Life Sciences at Warwick where his research interests are primarily studying protein ligand interactions with an interest in drug discovery projects.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.